vs
凯勒威廉姆斯（CTO）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是凯勒威廉姆斯的1.8倍（$75.5M vs $41.2M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 15.0%），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 19.5%）
凯勒威廉姆斯地产是一家美国科技企业及跨国房地产特许经营商，总部位于得克萨斯州奥斯汀。截至2022年，按销售额计算，它是美国规模最大的房地产特许经营机构，业务覆盖全球多个地区。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
CTO vs PBYI — 直观对比
营收规模更大
PBYI
是对方的1.8倍
$41.2M
营收增速更快
PBYI
高出12.7%
15.0%
两年增速更快
PBYI
近两年复合增速
19.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $41.2M | $75.5M |
| 净利润 | $6.2M | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | 175.0% | 22.7% |
| 净利率 | 15.1% | — |
| 营收同比 | 15.0% | 27.7% |
| 净利润同比 | 174.4% | — |
| 每股收益（稀释后） | $0.13 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTOPBYI
| Q1 26 | $41.2M | — | ||
| Q4 25 | $38.3M | $75.5M | ||
| Q3 25 | $37.8M | $54.5M | ||
| Q2 25 | $37.6M | $52.4M | ||
| Q1 25 | $35.8M | $46.0M | ||
| Q4 24 | $35.7M | $59.1M | ||
| Q3 24 | $31.8M | $80.5M | ||
| Q2 24 | $28.8M | $47.1M |
净利润CTOPBYI
| Q1 26 | $6.2M | — | ||
| Q4 25 | $28.3M | — | ||
| Q3 25 | $2.9M | $8.8M | ||
| Q2 25 | $-23.4M | $5.9M | ||
| Q1 25 | $2.3M | $3.0M | ||
| Q4 24 | $-15.2M | — | ||
| Q3 24 | $6.2M | $20.3M | ||
| Q2 24 | $1.2M | $-4.5M |
毛利率CTOPBYI
| Q1 26 | — | — | ||
| Q4 25 | 75.0% | 69.3% | ||
| Q3 25 | 75.4% | 77.7% | ||
| Q2 25 | 73.0% | 76.5% | ||
| Q1 25 | 75.2% | 77.1% | ||
| Q4 24 | 74.4% | 76.4% | ||
| Q3 24 | 74.4% | 63.9% | ||
| Q2 24 | 71.1% | 77.4% |
营业利润率CTOPBYI
| Q1 26 | 175.0% | — | ||
| Q4 25 | 75.1% | 22.7% | ||
| Q3 25 | 26.6% | 17.6% | ||
| Q2 25 | -33.7% | 12.7% | ||
| Q1 25 | 22.0% | 8.7% | ||
| Q4 24 | -20.4% | 22.6% | ||
| Q3 24 | 15.6% | 27.4% | ||
| Q2 24 | 18.8% | -4.6% |
净利率CTOPBYI
| Q1 26 | 15.1% | — | ||
| Q4 25 | 73.9% | — | ||
| Q3 25 | 7.7% | 16.2% | ||
| Q2 25 | -62.2% | 11.2% | ||
| Q1 25 | 6.3% | 6.5% | ||
| Q4 24 | -42.6% | — | ||
| Q3 24 | 19.6% | 25.2% | ||
| Q2 24 | 4.1% | -9.6% |
每股收益（稀释后）CTOPBYI
| Q1 26 | $0.13 | — | ||
| Q4 25 | $0.81 | $0.26 | ||
| Q3 25 | $0.03 | $0.17 | ||
| Q2 25 | $-0.77 | $0.12 | ||
| Q1 25 | $0.01 | $0.06 | ||
| Q4 24 | $-0.69 | $0.40 | ||
| Q3 24 | $0.17 | $0.41 | ||
| Q2 24 | $-0.03 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.3M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $575.4M | $130.3M |
| 总资产 | $1.3B | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资CTOPBYI
| Q1 26 | $8.3M | — | ||
| Q4 25 | $6.5M | $97.5M | ||
| Q3 25 | $9.3M | $94.4M | ||
| Q2 25 | $8.6M | $96.0M | ||
| Q1 25 | $8.4M | $93.2M | ||
| Q4 24 | $9.0M | $101.0M | ||
| Q3 24 | $8.2M | $96.7M | ||
| Q2 24 | $4.8M | $96.8M |
总债务CTOPBYI
| Q1 26 | — | — | ||
| Q4 25 | $616.3M | $22.7M | ||
| Q3 25 | $604.2M | $34.0M | ||
| Q2 25 | $605.4M | $45.3M | ||
| Q1 25 | $602.2M | $56.7M | ||
| Q4 24 | $519.0M | $68.0M | ||
| Q3 24 | $526.8M | $79.3M | ||
| Q2 24 | $482.7M | $90.7M |
股东权益CTOPBYI
| Q1 26 | $575.4M | — | ||
| Q4 25 | $567.3M | $130.3M | ||
| Q3 25 | $557.3M | $115.3M | ||
| Q2 25 | $574.1M | $104.7M | ||
| Q1 25 | $593.9M | $97.1M | ||
| Q4 24 | $612.8M | $92.1M | ||
| Q3 24 | $595.8M | $71.1M | ||
| Q2 24 | $491.8M | $48.5M |
总资产CTOPBYI
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $216.3M | ||
| Q3 25 | $1.2B | $202.9M | ||
| Q2 25 | $1.2B | $194.9M | ||
| Q1 25 | $1.2B | $196.2M | ||
| Q4 24 | $1.2B | $213.3M | ||
| Q3 24 | $1.2B | $220.7M | ||
| Q2 24 | $1.0B | $205.0M |
负债/权益比CTOPBYI
| Q1 26 | — | — | ||
| Q4 25 | 1.09× | 0.17× | ||
| Q3 25 | 1.08× | 0.30× | ||
| Q2 25 | 1.05× | 0.43× | ||
| Q1 25 | 1.01× | 0.58× | ||
| Q4 24 | 0.85× | 0.74× | ||
| Q3 24 | 0.88× | 1.12× | ||
| Q2 24 | 0.98× | 1.87× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $14.4M |
| 自由现金流经营现金流 - 资本支出 | — | $14.4M |
| 自由现金流率自由现金流/营收 | — | 19.1% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $41.7M |
8季度趋势，按日历期对齐
经营现金流CTOPBYI
| Q1 26 | — | — | ||
| Q4 25 | $64.6M | $14.4M | ||
| Q3 25 | $25.5M | $9.7M | ||
| Q2 25 | $21.9M | $14.1M | ||
| Q1 25 | $10.3M | $3.6M | ||
| Q4 24 | $59.9M | $15.6M | ||
| Q3 24 | $21.2M | $11.0M | ||
| Q2 24 | $12.9M | $1.0M |
自由现金流CTOPBYI
| Q1 26 | — | — | ||
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M |
自由现金流率CTOPBYI
| Q1 26 | — | — | ||
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% |
资本支出强度CTOPBYI
| Q1 26 | — | — | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% |
现金转化率CTOPBYI
| Q1 26 | — | — | ||
| Q4 25 | 2.28× | — | ||
| Q3 25 | 8.75× | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | 4.56× | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.40× | 0.54× | ||
| Q2 24 | 10.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
